drugset / Trial / NCT02261090

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

NCT02261090

Phase 1 Completed 14 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to compare the oral bioavailability of seven prototype slow-release formulations to immediate-release tablets

Timeline

Start
2004-06
Primary completion
2004-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 0.75 mg Oral

Indications

No indication recorded.